Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein

The mortality rates due to COVID-19 have been found disproportionate globally and are currently being researched. India mortality rate with a population of 1.3 billion people is relatively lowest to other countries with high infection rates. Genetic composition of circulating isolates continues to b...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Heliyon 2021-03, Vol.7 (3), p.e06564-e06564, Article e06564
Hauptverfasser: Alai, Shweta, Gujar, Nidhi, Joshi, Manali, Gautam, Manish, Gairola, Sunil
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e06564
container_issue 3
container_start_page e06564
container_title Heliyon
container_volume 7
creator Alai, Shweta
Gujar, Nidhi
Joshi, Manali
Gautam, Manish
Gairola, Sunil
description The mortality rates due to COVID-19 have been found disproportionate globally and are currently being researched. India mortality rate with a population of 1.3 billion people is relatively lowest to other countries with high infection rates. Genetic composition of circulating isolates continues to be a key determinant of virulence and pathogenesis. This study aimed to analyse the extent of divergence between genomes of Indian isolates (n = 2525 as compared to reference Wuhan-1 strain and isolates from countries showing higher fatality rates including France, Italy, Belgium, and the USA. The study also analyses the impact of key mutations on interactions with angiotensin converting enzyme 2 (ACE2) and panel of neutralizing monoclonal antibodies. Using 1,44,605 spike protein sequences, global prevalence of mutations in spike protein was observed. The study suggests that SARS-CoV-2 genomes from India share consensus with global trends with respect to D614G as most prevalent mutational event (81.66% among 2525 Indian isolates). Indian isolates did not reported prevalence of N439K mutation in receptor binding motif (RBM) as compared to global isolates (0.54%). Computational docking and molecular dynamics simulation analysis of N439K mutation with respect to ACE 2 binding and reactivity with RBM targeted antibodies viz., B38, BD23, CB6, P2B–F26 and EY6A suggests that variant have relatively higher affinity with ACE 2 receptor which may support higher infectivity. The study warrants large scale monitoring of Indian isolates as SARS-CoV-2 virus is expected to evolve and mutations may appear in unpredictable way. Receptor binding domain, COVID-19, SARS-CoV-2, Pandemic, Comparative genomics, Fatality rate, Clades, Neutralizing antibodies.
doi_str_mv 10.1016/j.heliyon.2021.e06564
format Article
fullrecord <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_proquest_miscellaneous_2504777369</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405844021006678</els_id><doaj_id>oai_doaj_org_article_3fd360950c7e48c08492e2c526f2b33f</doaj_id><sourcerecordid>2504777369</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-4aa144e4cc09143cb0a662313c01d60b5f9635d52824508a0fc255d802262b143</originalsourceid><addsrcrecordid>eNqNkl1v0zAUhiMEYtPYTwDlEgmlHH_GuQFNFR-VJoEYcInlOCedS2p3dlrUf49LSrVdwZWPjt_38bFfF8VzAjMCRL5ezW5xcPvgZxQomSFIIfmj4pxyEJXiHB7fq8-Ky5RWAECEkk3NnhZnjNVC1UqcFz8-G18tfOdM6cMOh9KGGLzZubhN5c3Vl5tqHr5XtFyiD2tnU2l8Vy6H0Jqh7NwOY3LjPjfNsE8ulc6XaeN-YrmJYUTnnxVPejMkvDyuF8W39---zj9W158-LOZX15UVjI0VN4ZwjtxaaAhntgUjJWWEWSCdhFb0jWSiE1RRLkAZ6C0VolNAqaRtdlwUi4nbBbPSm-jWJu51ME7_aYS41CaOzg6oWd8xCY0AWyNXFhRvKFIrqOxpy1ifWW8m1mbbrrGz6MdohgfQhzve3epl2Om6qamUh2FeHgEx3G0xjXrtksVhMB7DNmkqgNd1zWSTpWKS2hhSitifjiGgD1HrlT5GrQ9R6ynq7Htxf8aT62-wWfBqEvzCNvTJOvQWT7L8GSSrlSQ8V3DAqf9Xz91oRhf8PGz9mK1vJyvmeHcOoz7aOxfRjvn93T_u8hvjmN1F</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2504777369</pqid></control><display><type>article</type><title>Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein</title><source>DOAJ Directory of Open Access Journals</source><source>Web of Science - Science Citation Index Expanded - 2021&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Alai, Shweta ; Gujar, Nidhi ; Joshi, Manali ; Gautam, Manish ; Gairola, Sunil</creator><creatorcontrib>Alai, Shweta ; Gujar, Nidhi ; Joshi, Manali ; Gautam, Manish ; Gairola, Sunil</creatorcontrib><description>The mortality rates due to COVID-19 have been found disproportionate globally and are currently being researched. India mortality rate with a population of 1.3 billion people is relatively lowest to other countries with high infection rates. Genetic composition of circulating isolates continues to be a key determinant of virulence and pathogenesis. This study aimed to analyse the extent of divergence between genomes of Indian isolates (n = 2525 as compared to reference Wuhan-1 strain and isolates from countries showing higher fatality rates including France, Italy, Belgium, and the USA. The study also analyses the impact of key mutations on interactions with angiotensin converting enzyme 2 (ACE2) and panel of neutralizing monoclonal antibodies. Using 1,44,605 spike protein sequences, global prevalence of mutations in spike protein was observed. The study suggests that SARS-CoV-2 genomes from India share consensus with global trends with respect to D614G as most prevalent mutational event (81.66% among 2525 Indian isolates). Indian isolates did not reported prevalence of N439K mutation in receptor binding motif (RBM) as compared to global isolates (0.54%). Computational docking and molecular dynamics simulation analysis of N439K mutation with respect to ACE 2 binding and reactivity with RBM targeted antibodies viz., B38, BD23, CB6, P2B–F26 and EY6A suggests that variant have relatively higher affinity with ACE 2 receptor which may support higher infectivity. The study warrants large scale monitoring of Indian isolates as SARS-CoV-2 virus is expected to evolve and mutations may appear in unpredictable way. Receptor binding domain, COVID-19, SARS-CoV-2, Pandemic, Comparative genomics, Fatality rate, Clades, Neutralizing antibodies.</description><identifier>ISSN: 2405-8440</identifier><identifier>EISSN: 2405-8440</identifier><identifier>DOI: 10.1016/j.heliyon.2021.e06564</identifier><identifier>PMID: 33758785</identifier><language>eng</language><publisher>CAMBRIDGE: Elsevier Ltd</publisher><subject>Clades ; Comparative genomics ; COVID-19 ; Fatality rate ; Multidisciplinary Sciences ; Neutralizing antibodies ; Pandemic ; Receptor binding domain ; SARS-CoV-2 ; Science &amp; Technology ; Science &amp; Technology - Other Topics</subject><ispartof>Heliyon, 2021-03, Vol.7 (3), p.e06564-e06564, Article e06564</ispartof><rights>2021 The Author(s)</rights><rights>2021 The Author(s).</rights><rights>2021 The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>18</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000637861400004</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c533t-4aa144e4cc09143cb0a662313c01d60b5f9635d52824508a0fc255d802262b143</citedby><cites>FETCH-LOGICAL-c533t-4aa144e4cc09143cb0a662313c01d60b5f9635d52824508a0fc255d802262b143</cites><orcidid>0000-0002-4255-2474 ; 0000-0003-4824-2562</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972664/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972664/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,2106,2118,27933,27934,39267,53800,53802</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33758785$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alai, Shweta</creatorcontrib><creatorcontrib>Gujar, Nidhi</creatorcontrib><creatorcontrib>Joshi, Manali</creatorcontrib><creatorcontrib>Gautam, Manish</creatorcontrib><creatorcontrib>Gairola, Sunil</creatorcontrib><title>Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein</title><title>Heliyon</title><addtitle>HELIYON</addtitle><addtitle>Heliyon</addtitle><description>The mortality rates due to COVID-19 have been found disproportionate globally and are currently being researched. India mortality rate with a population of 1.3 billion people is relatively lowest to other countries with high infection rates. Genetic composition of circulating isolates continues to be a key determinant of virulence and pathogenesis. This study aimed to analyse the extent of divergence between genomes of Indian isolates (n = 2525 as compared to reference Wuhan-1 strain and isolates from countries showing higher fatality rates including France, Italy, Belgium, and the USA. The study also analyses the impact of key mutations on interactions with angiotensin converting enzyme 2 (ACE2) and panel of neutralizing monoclonal antibodies. Using 1,44,605 spike protein sequences, global prevalence of mutations in spike protein was observed. The study suggests that SARS-CoV-2 genomes from India share consensus with global trends with respect to D614G as most prevalent mutational event (81.66% among 2525 Indian isolates). Indian isolates did not reported prevalence of N439K mutation in receptor binding motif (RBM) as compared to global isolates (0.54%). Computational docking and molecular dynamics simulation analysis of N439K mutation with respect to ACE 2 binding and reactivity with RBM targeted antibodies viz., B38, BD23, CB6, P2B–F26 and EY6A suggests that variant have relatively higher affinity with ACE 2 receptor which may support higher infectivity. The study warrants large scale monitoring of Indian isolates as SARS-CoV-2 virus is expected to evolve and mutations may appear in unpredictable way. Receptor binding domain, COVID-19, SARS-CoV-2, Pandemic, Comparative genomics, Fatality rate, Clades, Neutralizing antibodies.</description><subject>Clades</subject><subject>Comparative genomics</subject><subject>COVID-19</subject><subject>Fatality rate</subject><subject>Multidisciplinary Sciences</subject><subject>Neutralizing antibodies</subject><subject>Pandemic</subject><subject>Receptor binding domain</subject><subject>SARS-CoV-2</subject><subject>Science &amp; Technology</subject><subject>Science &amp; Technology - Other Topics</subject><issn>2405-8440</issn><issn>2405-8440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl1v0zAUhiMEYtPYTwDlEgmlHH_GuQFNFR-VJoEYcInlOCedS2p3dlrUf49LSrVdwZWPjt_38bFfF8VzAjMCRL5ezW5xcPvgZxQomSFIIfmj4pxyEJXiHB7fq8-Ky5RWAECEkk3NnhZnjNVC1UqcFz8-G18tfOdM6cMOh9KGGLzZubhN5c3Vl5tqHr5XtFyiD2tnU2l8Vy6H0Jqh7NwOY3LjPjfNsE8ulc6XaeN-YrmJYUTnnxVPejMkvDyuF8W39---zj9W158-LOZX15UVjI0VN4ZwjtxaaAhntgUjJWWEWSCdhFb0jWSiE1RRLkAZ6C0VolNAqaRtdlwUi4nbBbPSm-jWJu51ME7_aYS41CaOzg6oWd8xCY0AWyNXFhRvKFIrqOxpy1ifWW8m1mbbrrGz6MdohgfQhzve3epl2Om6qamUh2FeHgEx3G0xjXrtksVhMB7DNmkqgNd1zWSTpWKS2hhSitifjiGgD1HrlT5GrQ9R6ynq7Htxf8aT62-wWfBqEvzCNvTJOvQWT7L8GSSrlSQ8V3DAqf9Xz91oRhf8PGz9mK1vJyvmeHcOoz7aOxfRjvn93T_u8hvjmN1F</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Alai, Shweta</creator><creator>Gujar, Nidhi</creator><creator>Joshi, Manali</creator><creator>Gautam, Manish</creator><creator>Gairola, Sunil</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4255-2474</orcidid><orcidid>https://orcid.org/0000-0003-4824-2562</orcidid></search><sort><creationdate>20210301</creationdate><title>Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein</title><author>Alai, Shweta ; Gujar, Nidhi ; Joshi, Manali ; Gautam, Manish ; Gairola, Sunil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-4aa144e4cc09143cb0a662313c01d60b5f9635d52824508a0fc255d802262b143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clades</topic><topic>Comparative genomics</topic><topic>COVID-19</topic><topic>Fatality rate</topic><topic>Multidisciplinary Sciences</topic><topic>Neutralizing antibodies</topic><topic>Pandemic</topic><topic>Receptor binding domain</topic><topic>SARS-CoV-2</topic><topic>Science &amp; Technology</topic><topic>Science &amp; Technology - Other Topics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alai, Shweta</creatorcontrib><creatorcontrib>Gujar, Nidhi</creatorcontrib><creatorcontrib>Joshi, Manali</creatorcontrib><creatorcontrib>Gautam, Manish</creatorcontrib><creatorcontrib>Gairola, Sunil</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Heliyon</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alai, Shweta</au><au>Gujar, Nidhi</au><au>Joshi, Manali</au><au>Gautam, Manish</au><au>Gairola, Sunil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein</atitle><jtitle>Heliyon</jtitle><stitle>HELIYON</stitle><addtitle>Heliyon</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>7</volume><issue>3</issue><spage>e06564</spage><epage>e06564</epage><pages>e06564-e06564</pages><artnum>e06564</artnum><artnum>06564</artnum><issn>2405-8440</issn><eissn>2405-8440</eissn><abstract>The mortality rates due to COVID-19 have been found disproportionate globally and are currently being researched. India mortality rate with a population of 1.3 billion people is relatively lowest to other countries with high infection rates. Genetic composition of circulating isolates continues to be a key determinant of virulence and pathogenesis. This study aimed to analyse the extent of divergence between genomes of Indian isolates (n = 2525 as compared to reference Wuhan-1 strain and isolates from countries showing higher fatality rates including France, Italy, Belgium, and the USA. The study also analyses the impact of key mutations on interactions with angiotensin converting enzyme 2 (ACE2) and panel of neutralizing monoclonal antibodies. Using 1,44,605 spike protein sequences, global prevalence of mutations in spike protein was observed. The study suggests that SARS-CoV-2 genomes from India share consensus with global trends with respect to D614G as most prevalent mutational event (81.66% among 2525 Indian isolates). Indian isolates did not reported prevalence of N439K mutation in receptor binding motif (RBM) as compared to global isolates (0.54%). Computational docking and molecular dynamics simulation analysis of N439K mutation with respect to ACE 2 binding and reactivity with RBM targeted antibodies viz., B38, BD23, CB6, P2B–F26 and EY6A suggests that variant have relatively higher affinity with ACE 2 receptor which may support higher infectivity. The study warrants large scale monitoring of Indian isolates as SARS-CoV-2 virus is expected to evolve and mutations may appear in unpredictable way. Receptor binding domain, COVID-19, SARS-CoV-2, Pandemic, Comparative genomics, Fatality rate, Clades, Neutralizing antibodies.</abstract><cop>CAMBRIDGE</cop><pub>Elsevier Ltd</pub><pmid>33758785</pmid><doi>10.1016/j.heliyon.2021.e06564</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-4255-2474</orcidid><orcidid>https://orcid.org/0000-0003-4824-2562</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2405-8440
ispartof Heliyon, 2021-03, Vol.7 (3), p.e06564-e06564, Article e06564
issn 2405-8440
2405-8440
language eng
recordid cdi_proquest_miscellaneous_2504777369
source DOAJ Directory of Open Access Journals; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Clades
Comparative genomics
COVID-19
Fatality rate
Multidisciplinary Sciences
Neutralizing antibodies
Pandemic
Receptor binding domain
SARS-CoV-2
Science & Technology
Science & Technology - Other Topics
title Pan-India novel coronavirus SARS-CoV-2 genomics and global diversity analysis in spike protein
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T06%3A25%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pan-India%20novel%20coronavirus%20SARS-CoV-2%20genomics%20and%20global%20diversity%20analysis%20in%20spike%20protein&rft.jtitle=Heliyon&rft.au=Alai,%20Shweta&rft.date=2021-03-01&rft.volume=7&rft.issue=3&rft.spage=e06564&rft.epage=e06564&rft.pages=e06564-e06564&rft.artnum=e06564&rft.issn=2405-8440&rft.eissn=2405-8440&rft_id=info:doi/10.1016/j.heliyon.2021.e06564&rft_dat=%3Cproquest_webof%3E2504777369%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2504777369&rft_id=info:pmid/33758785&rft_els_id=S2405844021006678&rft_doaj_id=oai_doaj_org_article_3fd360950c7e48c08492e2c526f2b33f&rfr_iscdi=true